Maggie L. Shaw

That lecanemab (Leqembi; Eisai/Biogen) is administered solely through weight-based dosing (10 mg/kg) and only offered in single-use vials of 200 mg and 500 mg may be to blame for the predicted $133 million to $336 million in wasted, and wasteful, […]

Potential reasons for delayed treatment initiation of guideline-directed oral medications to treat multiple myeloma (MM), and that demonstrate significant disparities to work at overcoming, include being of an older age and Black race, according to study results in Blood Cancer

At our recent Institute for Value-Based Medicine® event in Boston, the theme of the evening’s presentations was “Elevating Value in Cancer Care,” with 4 disease states and clinical areas serving as case studies for this outcome: non–small cell lung cancer,

The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the

Hereditary breast cancer, which accounts for 5% to 10% of all cases of breast cancer,1 is the direct result of a genetic predisposition to a higher lifetime risk of breast cancer due to its inherent inherited nature compared with the

There is not a relationship between hidradenitis suppurativa and infertility, according to new research comparing outcomes among 3 patient groups—55 patients with hidradenitis suppurativa, 55 patients with other dermatological diseases (ODDs), and 51 health patients in the control group. Among

The FDA has approved nivolumab (Opdivo; Bristol Myers Squibb) for adult patients who are node positive or have resectable non–small cell lung cancer (NSCLC) tumors that are at least 4 cm but who do not have EGFR mutations or ALK

The final podcast of our National Recovery Month series with UPMC Health Plan focused on the subject of trauma and knowledge of its impact on the behavioral health care space, as well as how both have facilitated positive change among

On September 20, the FDA approved isatuximab (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide (Revlimid; Celgene), and dexamethasone (VRd) in the first line for patients who have multiple myeloma and are ineligible for transplant. This approval came a full week

First set in 2014, the 90-90-90 program from UNAIDS had 3 goals: diagnose 90% of people living with HIV, provide antiretroviral therapy (ART) for 90% of diagnosed patients, and achieve viral suppression for 90% of patients on treatment.1 These goals